ProShares Ultra Nasdaq Biotechnology Declares Quarterly Dividend of $0.01 (NASDAQ:BIB)

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) declared a quarterly dividend on Tuesday, March 24th. Shareholders of record on Wednesday, March 25th will be paid a dividend of 0.0071 per share by the exchange traded fund on Tuesday, March 31st. This represents a c) dividend on an annualized basis and a yield of 0.0%. The ex-dividend date of this dividend is Wednesday, March 25th.

ProShares Ultra Nasdaq Biotechnology Stock Up 5.3%

Shares of NASDAQ:BIB traded up $3.93 during trading on Wednesday, hitting $78.73. 13,645 shares of the company traded hands, compared to its average volume of 12,167. The stock has a market capitalization of $82.67 million, a price-to-earnings ratio of 20.68 and a beta of 1.38. The business’s fifty day moving average is $83.63 and its 200-day moving average is $76.03. ProShares Ultra Nasdaq Biotechnology has a one year low of $33.78 and a one year high of $90.90.

Institutional Trading of ProShares Ultra Nasdaq Biotechnology

Large investors have recently modified their holdings of the company. Franklin Resources Inc. bought a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the 2nd quarter worth about $32,000. Citadel Advisors LLC acquired a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the 3rd quarter worth approximately $307,000. Kaizen Financial Strategies bought a new position in shares of ProShares Ultra Nasdaq Biotechnology in the fourth quarter valued at approximately $424,000. Palumbo Wealth Management LLC bought a new position in shares of ProShares Ultra Nasdaq Biotechnology in the third quarter valued at approximately $766,000. Finally, Laurel Wealth Advisors LLC increased its stake in shares of ProShares Ultra Nasdaq Biotechnology by 4,481.0% during the second quarter. Laurel Wealth Advisors LLC now owns 13,743 shares of the exchange traded fund’s stock valued at $630,000 after acquiring an additional 13,443 shares during the period.

About ProShares Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.